1 / 46

DISULFIRAM Comparative Studies and Experiences from Clinical Practice

DISULFIRAM Comparative Studies and Experiences from Clinical Practice . Dr. Avinash De Sousa. My work in India. State government aided hospital. Private psychiatric set up – nursing home . Out patient private practice. Private general hospital with a large psychiatric set up.

gent
Download Presentation

DISULFIRAM Comparative Studies and Experiences from Clinical Practice

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. DISULFIRAM Comparative StudiesandExperiences from Clinical Practice Dr. Avinash De Sousa

  2. My work in India • State government aided hospital. • Private psychiatric set up – nursing home. • Out patient private practice. • Private general hospital with a large psychiatric set up.

  3. Alcohol Dependence in India • No major research available on long term management till last five years. • Few doctors interested in specializing in addiction medicine. • Indian culture and alcohol dependence.

  4. Disulfiram in India • Cheaper alternative to Naltrexone, Acamprosate and Topiramate. • Alcoholism is a very rampant problems and most patients are the sole bread winners. • Abstinence is very important for work. • Lack of aided psychiatric services.

  5. Disulfiram in India • Though cheaper – few psychiatrists are comfortable with usage. • Side effects are rare – hepatotoxicity or neuropathy. • Complicated alcohol withdrawals are common in our practice. • Disulfiram induced confusion or psychosis.

  6. The Indian Studies • Three open randomized trials (2004-2008) Naltrexone VS Disulfiram Acamprosate VS Disulfiram Topiramate VS Disulfiram • Conditions in the study were similar to routine clinical practice in India. • All patients – underwent detoxification. • Randomized but open study.

  7. Inclusion Criteria • Age between 18-65 years. • DSM-IV criteria for alcohol dependence. • All had a stable and supportive family environment. • One responsible family member. • Importance of supervised Disulfiram therapy

  8. Exclusion Criteria • Other substance use disorders other than Nicotine Dependence. • Any co-morbid psychiatric disorder. • Any medical condition that would interfere with compliance. • Elevated liver functions. • Previous treatment with the 2 drugs of the study.

  9. Methodology • Subjects informed about the study and the drugs involved. • Need for a family member to be present on regular follow up. • Importance of psychoeducation in Disulfiram therapy.

  10. Procedure & Assessments • Addiction Severity Index. • Severity of Alcohol Dependence Scale. • Scale to measure the 3 parameters of craving frequency, duration and intensity – (Anton). • Baseline liver function tests. • Calendar to record alcohol consumption.

  11. Dose of medication used • 50mg of Naltrexone once a day. • 250mg of Disulfiram once a day. • 666mg of Acamprosate thrice daily. • 50mg Topiramate thrice daily. • NTX and DSF taken as a single daily dose in the morning after breakfast with a family member to observe that the patient takes the medicine.

  12. Follow ups • Weekly for the first 3 months. • Fortnightly till the end of the study. • Transport paid by us – other incentive offered. • Supportive group psychotherapy – once a week – less structured than in a classical de-addiction programme – emphasis on compliance.

  13. Additional medications • Sertraline 50-100mg and • Escitalopram5-10mg in case of depression. • Duloxetine 20-40mg per day in the Topiramate study. • Zolpidem 5-10mg at night in case of insomnia. • No benzodiazepines were prescribed.

  14. Outcome measures • Accumulated days of abstinence. • Days until the first relapse (defined as consuming more than 5 alcoholic drinks or 40gm alcohol in 24 hours).

  15. Outcome Measures • Craving measures. • GGT measured every 3 months. • Discontinuation of treatment. • Drop out from the study

  16. DisulfiramVSNaltrexone(Alcohol & Alcoholism 2004 ; 39(6) : 528-531)

  17. Clinical Variables at start

  18. Clinical Variables at start

  19. Outcomes at the end of 1 year

  20. Outcomes at the end of 1 year

  21. DisulfiramVSAcamprosate(Alcohol & Alcoholism 2005 ; 40(6) : 545-548)

  22. Clinical Variables at start

  23. Clinical Variables at start

  24. Outcomes at the end of 1 year

  25. Outcomes at the end of 1 year

  26. DisulfiramVSTopiramate( J Subs Abuse Treatment 2008; 34 : 460-463)

  27. Clinical Variables at start

  28. Clinical Variables at start

  29. Outcomes at the end of 1 year

  30. Outcomes at the end of 1 year

  31. Discussion • All three drugs were well tolerated. • Larger studies across diverse populations of patients are needed to replicate and strengthen these results. • Family support in India is strong – exploiting this resource is a must in the successful use of Disulfiram.

  32. Other studies done by us • Disulfiram superior to Naltrexone in elderly alcoholics. (Journal of Pakistan Psychiatric Society 2009) • Disulfiram superior to Naltrexone in adolescent alcohol dependence patients. (Journal of Substance Use 2006) • Disulfiramsuperior to Naltrexone in female alcoholics. (unpublished work)

  33. Studies in progress • Disulfiram versus a Combined Naltrexone and Acamprosate regime • Does Acamprosate addition enhance Disulfiram therapy. • Disulfiram and Psychotherapy. (All studies would be complete by 2011-2012)

  34. Other pivotal studies • The Helsinki Disulfiram study. • Disulfiram superior to Acamprosate. • OLITA Study. • Other small but important studies.

  35. Limitations • Open studies rather than a blinded ones. Hypothetically a bias may have been introduced. • No laboratory marker used to assess compliance. • Good primary support group leading to fewer drop outs. • Stringent inclusion criteria.

  36. Other issues in Disulfiram therapy • Incorporating Disulfiram into psychotherapy. • Disulfiram in patients with comorbid psychiatric disorders. • Where does Disulfiram stand today in the modern pharmacotherapy of alcoholism.

  37. Conclusions • Disulfiram is a treatment option that cannot be ignored. • Psychiatrists worldwide need to be trained. • Oral DisulfiramVS Long acting Naltrexone or Naltrexone implants • Effective compliance monitoring.

  38. Acknowledgements • The Stapleford Conference and its organizers. • My parents who have taught me most of my psychiatry. • My country that gives me enough freedom and patients who trust me fully. • Everyone here who made me feel at home.

More Related